Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
191
resultados
Última actualización
30/09/2025 [06:51:00]
Resultados 100 a 125 de 191
Resumen de: CN120665295A
本发明公开了一种响应型阳离子化二维纳米催化转染剂的制备方法及应用，属于生物学领域。本发明所公开的转染剂以二维MXene（如碳化铌）为基体，表面依次修饰多氨基阳离子聚合物（如枝状聚乙烯亚胺）和醛基聚乙二醇（CHO‑PEG‑CHO），形成具有pH响应性的PNb2C@PEG。其制备方法包括Nb2C纳米片剥离、PEI阳离子化、PEG屏蔽修饰等步骤。材料表征显示，该转染剂在pH7.4时电位为‑12.5mV（屏蔽正电荷），在pH6.5时电位转为+14.0mV（响应肿瘤酸性微环境），且具有催化活性氧分解能力，可保护细胞免受氧化损伤。与传统阳离子脂质体相比，其转染效率相当，但毒性显著降低，原料成本低、基因载量高，适用于基因递送领域。
Resumen de: CN120664979A
本发明本发明属于生物医药技术领域，涉及药物递送技术，具体涉及一类基于衣康酸母核母核的可电离脂质或其药学上可接受的盐、其异构体、其溶剂合物，及其制备方法和应用。实验结果显示，本发明采用基于衣康酸母核的可电离脂质或其药学上可接受的盐、其异构体、其溶剂合物制成的脂质纳米颗粒，转染效率更高，包封效果好，药物递送能力强。
Resumen de: CN120661679A
本发明公开了一种脂质体纳米颗粒及其制备方法和应用，涉及生物医药领域。该脂质体纳米颗粒包括修饰有融合蛋白的脂质复合物，融合蛋白包括载脂蛋白E或其多肽与抗体，融合蛋白的修饰不仅能够主动靶向相应配体的细胞、组织或器官，还能有效提高脂质体纳米颗粒对细胞的转染效率和靶向递送能力，实现核酸药物的高效递送，可应用于制备抗肿瘤药物。
Resumen de: CN120661471A
本发明涉及一种外泌体包裹的含磷树状大分子纳米复合物及其制备方法和应用，所述纳米复合物由间充质干细胞来源的外泌体、羟基端含磷树状大分子以及槲皮素构成。本发明以间充质干细胞来源的外泌体作为载体，不仅具有良好的生物相容性和抗炎活性，还可提高含磷树状大分子和槲皮素的生物利用度。含磷树状大分子和槲皮素通过促进小胶质细胞向M2型极化和清除活性氧发挥抗炎和抗氧化作用，进而保护神经元细胞免受凋亡。本发明具有制备方法简单、易于操作、生物相容性好等优点，提供的策略可在治疗帕金森病或其它神经退行性疾病中具有良好的发展前景和应用价值。
Resumen de: AU2024223881A1
The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.
Resumen de: CN120661470A
本发明公开了一种适用于肿瘤疫苗接种的脾脏靶向纳米平台构建方法，具体涉及疫苗领域，包括S1、选择CL15H6‑DOPS LNPs、球形聚合物囊泡、红细胞膜包被纳米颗粒作为脾脏靶向纳米载体；S2、整合免疫佐剂；选择Mn2+掺杂LNPs、超声响应脂质体和CD3抗体偶联作为整合材料；S3、体内递送；选择动物模型进行体内递送和疗效验证，动物模型分别选择B16F10黑色素瘤小鼠、MC38结肠癌小鼠和非人灵长类。本发明通过优化脂质体链长和表面拓扑结构(如球形聚合物囊泡)，显著提升脾脏富集率，增强红髓髓系细胞摄取效率。结合锰佐剂共同递送，激活STING通路并促进I型干扰素分泌，提升抗原特异性CD8+T细胞比例和肿瘤抑制率。
Resumen de: AU2023387789A1
Provided herein is a lipid nanoparticle encapsulating nucleic acid and having at least 30 mol% neutral lipid, a sterol or derivative thereof and a targeting moiety anchored in a lipid layer thereof via a lipophilic moiety. Further provided are methods of using the lipid nanoparticles for targeted delivery in vivo. Such lipid nanoparticle may exhibit significantly improved delivery and targeting to extrahepatic tissues and/or organs.
Resumen de: CN120661474A
本发明涉及一种左旋多巴脂质纳米粒、鼻喷雾剂及其制备方法。该左旋多巴脂质纳米粒，由左旋多巴、棕榈酸棕榈酯和和含表面活性剂的水溶液制备而成；所述左旋多巴和棕榈酸棕榈酯的质量比为1：5‑35。将该脂质纳米粒配合特定的辅料羧甲基壳聚糖，制备得到了一种黏度适中的左旋多巴脂质纳米粒鼻喷雾剂，该鼻喷雾剂具有合适的雾滴粒径和喷雾面积，使左旋多巴药物具有较高的嗅区沉积率，能够有效提高左旋多巴的鼻‑脑递送效率，从而显著提高其对提高帕金森病的治疗效果，并且减少药物的外周毒副作用。
Resumen de: CN120665018A
本发明公开了一种可生物降解碱基脂质及其制备方法与应用，其结构式如式(Ⅰ)所示：(Ⅰ)，其中，极性头部基团为碱基基团，为天然嘌呤或嘧啶碱基；n1选自1‑10的正整数；n2选自1‑10的正整数；n3选自1‑10的正整数；X为‑O‑或‑NH‑；R1为取代或未被取代的C6‑16烷基，或取代或未被取代的C6‑16烯基，或取代或未被取代的C6‑16炔基；R2为取代或未被取代的C6‑16烷基，或取代或未被取代的C6‑16烯基，或取代或未被取代的C6‑16炔基。本发明通过在脂质疏水尾部引入酯键结构，显著增强了脂质化合物的生物可降解性，同时保留了其高效核酸递送能力。
Resumen de: CN120665191A
本发明公开了一种工程化脐带干细胞及其在制备抗衰老药物和医美产品中的应用。通过设计融合多肽TAT‑SIRT1‑SOD(SEQ ID NO:1)与抗p16INK4a单克隆抗体(mAb‑p16)协同修饰脐带干细胞，结合3D动态培养技术，构建具有高效抗衰功能的工程化细胞体系。融合多肽通过TAT穿膜肽介导跨膜，激活SIRT1并清除线粒体ROS；mAb‑p16特异性结合衰老细胞表面p16INK4a，通过ADCC效应清除衰老细胞。实验表明，该工程化脐带干细胞可使衰老细胞清除率提升86.1％，SOD活性提高300％，显著抑制炎症因子IL‑6分泌，并在动物模型中使皮肤胶原密度提升148％、皱纹深度减少67％。本发明为抗衰老药物及医美产品提供了新型高效的技术方案。
Resumen de: CN119345399A
The invention discloses an exosome drug for treating premature ovarian failure as well as a preparation method and application of the exosome drug. The exosome drug is obtained by mixing LNP or TNP encapsulated with an mRNA composition encoding NAMPT, NMNAT3 and COX15 with an exosome of a specific targeting ovarian cell, animal experiments prove that the exosome medicine has a remarkable treatment effect on the premature ovarian failure, a new thought and strategy are provided for the technical field of premature ovarian failure treatment, and the clinical application prospect is wide.
Resumen de: CN120661534A
本发明公开了一种延缓衰老、保持皮肤年轻的组合物，所述的组合物包括PQQ、麦角硫因以及NAD+三种活性成分，其质量配比为1:1:1，其中：所述PQQ用于保护线粒体功能并促进新线粒体生成；所述麦角硫因通过OCTN1转运蛋白介导的细胞穿透机制延缓端粒缩短；所述NAD+用于激活Sirtuins蛋白家族并修复DNA损伤，本发明涉及医药技术领域，PQQ通过脂质纳米粒靶向递送，精准作用于线粒体，抵御95％以上自由基攻击，同时促进新生线粒体生成，从能量源头延缓细胞衰老，高纯度麦角硫因通过OCTN1转运蛋白穿透细胞膜，直达细胞核延缓端粒缩短，NAD+直接激活Sirtuins家族蛋白，修复DNA损伤效率提升60％，并显著提升皮肤胶原蛋白密度、心肌细胞活力，逆转生理年龄迹象。
Resumen de: US2024261223A1
Novel delivery nanoparticles composes of two-, or three-component lipid compounds. Compositions comprising such lipid compounds, and related methods of their use are disclosed. Nanoparticle compositions include at least one novel modular lipid as well as additional lipids such as ionizable lipids, and phospholipids. Nanoparticle compositions further including biologically active agents, such as siRNA or mRNA, are useful in the delivery of said biologically active agents to subjects in need thereof.
Resumen de: CN120661699A
本发明具体公开了肾小管上皮细胞膜包裹的纳米颗粒及其制备方法和应用，涉及生物医药技术领域。本发明提供了一种肾小管上皮细胞膜包裹的纳米颗粒(FNMs)，所述纳米颗粒包括肾小管细胞膜、造影剂和染料。FNMs在APOE‑/‑小鼠AS模型中能过精准靶向颈动脉斑块实现荧光/磁共振双模态成像，从多角度全面反映斑块出病变信息。克服了传统药物治疗的低生物利用度，传统手术治疗的高创伤风险。40μg/mL的浓度即能够在光照作用下产生PDT效应，实现减轻AS斑块病变的治疗效果。无论是在细胞实验中还是动物实验中，FNMs均展示了高生物安全性。
Resumen de: CN120664978A
本发明公开一种含氮链状化合物、制备方法、包含其的组合物和应用。本发明具体公开一种式I化合物或其药学上可接受的盐，其具有以下优势：制备得到的LNP制剂，纳米颗粒大小相对均匀，包封率较高，体内表达活性高。
Resumen de: CN120661472A
本发明属于生物医学工程与神经修复领域，更具体的说是脊髓损伤研究用磁性树突状细胞微型机器人递送模型的构建方法。该方法包括：(1)制备磁性树突状细胞微型机器人；(2)将所述磁性树突状细胞微型机器人通过尾静脉注射递送至实验动物体内；(3)在外部旋转磁场驱动下，将磁性树突状细胞微型机器人靶向至脊髓损伤部位；(4)评估脊髓损伤的病理机制或药物干预效果。通过外部旋转磁场的调控作用，可实现磁性树突状微型机器人在脊髓损伤区域的主动靶向定位，为中枢神经系统损伤的机制研究提供精准的递送路径。
Resumen de: CN120661627A
本发明公开了一种可治疗肝脏缺血再灌注损伤的纳米颗粒及其制备方法与应用。其中，所述纳米颗粒为多肽修饰的纳米颗粒，所述多肽含有如SEQ ID NO:1所示的氨基酸序列，并特异性结合TSP‑1。本发明制备得到的多肽修饰的纳米颗粒表征稳定，降低了肝脏缺血再灌注损伤中的损伤肝脏内TSP‑1富集、抑制损伤肝脏中的炎性细胞浸润水平以及细胞凋亡、对肝脏急性缺血再灌注损伤有抑制作用。
Resumen de: JP2024081767A
To provide a composition for preventing or treating diseases or symptoms associated with a reduction in the expression of peroxisome proliferator-activated receptor coactivator 1-alpha (PGC-1α).SOLUTION: The composition is provided comprising, as an active ingredient, a compound represented by the general formula I defined by S-(MS)p-(MS)q or a salt or solvate thereof, where S is sialic acid, and (MS)p and (MS)q each independently represent a monosaccharide residue.SELECTED DRAWING: Figure 1a
Resumen de: WO2024133892A1
A crosslinked vesicle comprising an outer layer and an inner core, said outer layer comprising a cationic amphiphilic peptide and said inner core comprising a fluorinated compound in liquid form, wherein said cationic amphiphilic peptide is a compound of formula (I) HB - CL - HP (I), wherein HB is a fluorinated hydrophobic block, CL is a cross-linking motif, HP is a cationic hydrophilic amino acid sequence having an alpha-helix structure and comprising at least (1) positive charge and said vesicle has a zeta potential of at least (20) mV.
Resumen de: CN120418280A
The present disclosure relates to combination therapies comprising an immune checkpoint inhibitor, a nanoparticle formulated plasmid comprising an IL-12 encoding nucleic acid, and optionally at least one adjuvant chemotherapeutic drug, as well as methods of treatment using such combination therapies and/or compositions.
Resumen de: AU2024214423A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.
Resumen de: AU2025205319A1
Methods of treating, reducing the risk of, preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by pulmonary administration of a cerium oxide nanoparticle composition. 5 Methods of treating, reducing the risk of, preventing, or alleviating a symptom of a pulmonary disease or condition, reducing or suppressing inflammation in the lung, and promoting lung repair, by pulmonary administration of a cerium oxide nanoparticle 5 composition. ul e t h o d s o f t r e a t i n g , r e d u c i n g t h e r i s k o f , p r e v e n t i n g , o r a l l e v i a t i n g a s y m p t o m o f a u l p u l m o n a r y d i s e a s e o r c o n d i t i o n , r e d u c i n g o r s u p p r e s s i n g i n f l a m m a t i o n i n t h e l u n g , a n d p r o m o t i n g l u n g r e p a i r , b y p u l m o n a r y a d m i n i s t r a t i o n o f a c e r i u m o x i d e n a n o p a r t i c l e c o m p o s i t i o n
Resumen de: WO2025194120A1
Provided herein are zwitterionic polymer (ZIP)-lipids and pharmaceutically-acceptable salts thereof; lipid nanoparticles (LNPs) comprising such ZIP-lipids; formulations comprising ZIP-lipid containing LNPs; methods of delivering ZIP-lipid containing LNPs, or formulations thereof, to a subject; and methods of treating a disease, dirsorder or condition comprising administering ZIP-lipid containing LNPs, or formulations thereof, to a subject.
Resumen de: WO2025193920A1
Disclosed herein are methods of preparing nanoparticles along with the nanoparticles and products made therefrom. In certain embodiments, the methods comprise complexing an agent with a protein or protein isolate to form a complexed solution and nanoprecipitating the complexed solution in a nanoprecipitation solvent to provide a nanoprecipitation solution comprising the nanoparticles.
Nº publicación: WO2025193934A1 18/09/2025
Solicitante:
UNIV CENTRAL FLORIDA RES FOUND INC [US]
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC
Resumen de: WO2025193934A1
Community-associated and hospital acquired infections caused by bacteria and viruses on surfaces are global challenges to human health. New strategies that offer non-specific and broad protection are urgently needed. Irradiated cerium nanoparticles IrCNPs are provided which optionally are synthesized with a metal such as silver. These nanoparticles are designed to have superior function due to a higher trivalent (Ce3+) surface fraction, which produces high potency and residual effects on a variety of surfaces. Preferred IrCNPs can rapidly and completely eradiate Pseudomonas aeruginosa, Staphylococcus aureus, and methicillin resistant S. aureus, both species and biofilm, within 3 hours of exposure, and are effective against viruses as well.
BOPI
Sede Electrónica
